ALK and neoplasm: Similarly to EGFR-mutant tumours progressing under TKIs, patients harbouring ALK rearrangements will ultimately acquire resistance to crizotinib due to a variety of mechanisms, with secondary ALK mutations representing the most investigated [47], and with CNS as one common site of metastatisation [48].